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Bone metastases: Remineralisation after radiotherapy or 
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In the event of malignancy skeletal involvement is common, 
being the third commonest site of metastatic disease after 
liver and lungs. Metastatic bone disease is associated with 
considerable morbidity and complications that may 
deteriorate the quality of life (QOL) of patients, reduce their 
functional capabilities and may even reduce overall survival.  
External beam RT is an established treatment modality for 
the management of bone metastases since decades, bringing 
about significant pain response and reduction in the skeletal 
complication rates. The effect of RT may be a result of the 
high level of inflammatory and tumor cell kill that is achieved 
and the consequent decrease in osteoclastic activity. 
Reossification and increased bone density in the area of 
metastatic bone lesions is considered to be an indication for 
successful treatment.  In the different published radiological 
response criteria (UICC, WHO and MDA) the level of re-
ossification describes the response classification. Importantly 
the level of reossification has been associated with an 
improved clinical response, a decreased level of suffering and 
pain, an Improved QOL and performance status and a 
decreased risk for pathologic fractures.  
Even though RT alone has shown to achieve significant 
increase in bone density in metastatic lesions, combination 
with other treatments such as Bps has shown to result in an 
enhanced level bone ossification (figure1). This is a result of 
the synergistic activity and common action of the two 
treatment modalities on osteoclasts that decreases their 
function and hinders bone destruction. Moreover the 
interruption of the vicious cycle enables osteoblasts to 
remodel and reossify ostoelytic lesions. This is associated 
with an improved therapeutic response and effectiveness. 
Moreover, a spatial cooperation is enabled, with RT 
controlling local bone lysis and Bps managing disease 
progression in skeletal regions away from the radiotherapy 
treatment field.  Enhanced ossification after the concomitant 
use of RT and Bps has also been shown in animal models. 
Notably their combined action was accompanied by an 
improved bone microarchitecture, bone volume and 
biomechanical strength.  
Denosumab has also shown to increase bone density and 
strength in patients with osteoporosis.  The effect is 
enhanced when combination treatment with teriparatide 
(recombinant form of parathyroid hormone) is used.  
In the published radiological response criteria bone density 
changes are not quantified.  This could be done by evaluating 
and measuring changes in Hounsfield units in the area of 
bone metastases. This may add to the overall treatment 
response assessment and help in determining the 
effectiveness of treatment. What is unquestionable is that 
remineralization is a very important endpoint that is an 
indication of a successful treatment. More over it was shown 
that it is accompanied by an improved clinical outcome, a 
reduction of possible skeletal complications and an improved 
bone microarchitecture and strength.   
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Figure one depicts the therapeutic outcome of a patient with 
breast cancer and a lytic lesion in the sacrum managed with 
combined RT and Bps (10 months administration). 
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Brain: SIB technique combinations with EBRT, outcome of 
newer systemic therapies 
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Standard management for patients with metastatic cancer to 
brain include comfort measures using medications such as 
dexamethasone.  Depending on patient factors (such as 
performance status) and metastatic disease extent, standard 
established local brain treatment includes surgery (for 
resectable single brain metastasis) and radiosurgery (for 
small metastatic disease to brain).  For extensive brain 
metastases and for patients who are not eligible for surgery 
or radiosurgery, whole brain radiotherapy is commonly used. 
The experimental strategy of simultaneous in-field/ 
integrated boost and a summary of newer systemic therapies 
used in the management of brain metastases will be 
reviewed. 
Further research is needed to assess whether these new 
technologies in the management of brain metastases improve 
survival and/ or quality of life. 
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In an era of increasing systemic therapy options for the 
management of patients diagnosed with non-small cell lung 
cancer (NSCLC) who are either not suitable for curative 
therapy or who present with metastatic disease, radiation 
therapy (RT) has an established role.  Specifically, 
conventional RT is an effective, well-tolerated and 
inexpensive treatment modality for the palliation of 
symptoms caused by locally advanced intrathoracic disease or 
arising due to systemic metastases (1). Technological 
advances, specifically the availability of stereotactic RT has 
offered the radiation oncologist a choice in mode of radiation 
delivery.  Stereotactic radiosurgery (SRS) is an increasingly 
important technique in the management of cerebral 
metastases and Stereotactic body RT (SBRT) is being offered 
to patients with oligometastatic disease.  There is no 
evidence to suggestion the SBRT offers outcomes superior to 
those achieve with conventionally fractionated RT although 
this question is being addressed in clinical trials. .  In 
addition, an emerging role for Stereotactic body RT (SBRT) in 
patients with oligometastatic disease is being postulated.  
SBRT by achieving good local control at metastatic sites may 
delay the time until further systemic therapy is warranted.   
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RT, is an effective way of achieving intrathoracic local 
control.  Patients with locally advanced or metastatic disease 
frequently experience morbidity or mortality due to the 
consequences of local disease progression.  Patients with 
large, central disease or compression of major bronchi or 
vessels were found to have worse overall survival (OS) in a 
pooled analysis of patients enrolled in clinical trials involving 
first-line, platinum-based chemotherapy, suggesting that 
improvement in local control with the addition of  thoracic 
RT to systemic therapy could improve OS. (2)   
Preclinical data suggests that the combination of molecularly 
targeted agents and RT increases radiation responsiveness.  
To date, the combination has not improved outcomes in 
clinical trials in patients with locally advanced NSCLC (3). 
Studies addressing the choice of agent to be used in 
combination and in particular the optimal sequencing of 
modalities are required. 
  
(1) Fairchild A et al: J Clin Oncol 2008: 26(24): 4001-4011. 
(2) Higginson, D et al: Int J Radiation Oncol Biol Phys 2012: 
84(3): 385. 
(3) Spigel D et al: J Clin Oncol 2010: 28: 43-8 
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Liver: Role of RFA, chemo-ablation and SBRT for liver 
metastases 
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Resection of liver metastases from colorectal carcinoma 
(CRC) is associated with 5 year survival rates of 
approximately 50% with the possibility for cure.  Although 
long term survivors have also been reported following 
resection of liver metastases from sarcoma, renal cell 
carcinoma, breast cancer and melanoma (5 year survival up 
to 36%), resection is not routinely accepted as standard of 
care.  As the risks of surgery increase, and the benefits of 
surgery decline, alternative local ablative therapies such as 
radiofrequency ablation (RFA) and stereotactic body 
radiation therapy (SBRT) are more attractive treatment 
options.    
Hepatic arterial directed chemotherapy (or chemo-ablation) 
has been used to treat liver metastases from CRC with better 
than expected results compared with systemic therapy in 
single institutional series, but there are no comparative 
studies with modern chemotherapy for CRC or other liver 
metastases.  This therapy is not considered ablative, with the 
potential to cure.  
Radiofrequency ablation (RFA) is an effective ablative 
technique for liver metastases treatment.  Local control is 
highest (> 80%) in selected metastases < 3 cm in maximal 
diameter.  Recurrences are common in metastases > 5 cm, or 
in metastases adjacent to large vessels that may act as a 
heat sink.  Primary toxicities include infection and bleeding.  
RFA of lesions near the common bile duct or diaphragm are 
associated with increased risks of serious toxicity.  
Stereotactic body radiation therapy (SBRT) is an attractive 
option for patients with liver metastases.  Short course, out-
patient SBRT delivered in 1 to 10 fractions is convenient for 
patients, with little ‘downtime’, and short systemic therapy 
break.  Liver SBRT requires a planning CT simulation scan 
with IV contrast and/or contrast-enhanced MRI for target 
delineation. Breathing related liver motion should be 
assessed by respiratory correlated (or 4D) CT, cine-MR 
imaging or 2D kV fluoroscopy to determine appropriate 
planning target volume (PTV) margins.  Highly conformal dose 
distributions are desirable using multiple beams or arcs, in 
coplanar or non-coplanar geometries.  Immobilization of the 
liver using controlled breath holds, abdominal compression, 
gating of the RT beam during specified phases of the 
respiratory cycle, medications, or tumor tracking may help 
reduce the adverse effects of breathing motion.  Image 
guided RT (IGRT) based on volumetric imaging such as kV 
cone beam CT, is required at every fraction in order to 
reduce PTV margins.  MR IGRT is an area of active research 
that may benefit liver SBRT.   
A Toronto SBRT study (24 – 48 Gy in 6 fractions) in 107 
patients with 172 inoperable liver metastases from colon, 
breast cancer or other sites (median volume 75 cc) had a 
median survival of 18.1 months.  Survival was worse in 
patients with extrahepatic disease (present in 43%).  
Improved local control was seen with breast cancer and 
higher doses.  Some patients appear cured > 5 years post 
SBRT.   Other SBRT series (30-60 Gy in 1-6 fractions) for < 5 
metastases (maximal size < 6 cm) have reported median 
survival rates from 18 to 37 months, and local control of 67% 
to 100%.   A dose response has been observed in most series, 
with increased chance of sustained local control (80 – 90% at 
2 years) when doses higher than 42 Gy in 3 fractions are 
used.  Local control is also improved in patients with 
metastases less than 3 cm in maximal size and in breast 
cancer metastases compared to colorectal cancer 
metastases.  Local control may be reduced in metastases 
adjacent to luminal gastrointestinal tissues.  SBRT has low 
acute and late toxicity (transient fatigue, nausea, gastritis or 
duodenitis), and very low risk of liver toxicity.  Chest wall 
and rib fractures have also occasionally been seen.  Studies 
have shown that quality of life is preserved 3 – 12 months 
post SBRT. The most suitable patients are those with 5 or 
fewer metastases, < 6 cm, with no extrahepatic disease.  
More research is required regarding optimal dose-per-
fraction, as well as most appropriate patient selection and 
sequencing with systemic therapy. 
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Tumour metabolism is a critical factor for molecular 
imaging  
J. Bussink1, T.W. Meijer1, J.H.A.M. Kaanders1, P.N. Span1 
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Radiotherapy induced tumor cell kill relies on induction of 
oxidative stress. The response to irradiation of malignant 
tumors vary as a consequence of resistance mechanisms 
taking place at the molecular level. The hypoxia-inducible 
factor 1 (HIF-1) pathway is involved in various of these 
processes. With respect to metabolism HIF-1 is an important 
regulator of glycolysis and the pentose phosphate pathway. 
This aberrant cellular metabolism, responsible for 
maintaining stable intracellular ATP levels without oxygen 
consumption even under normoxic conditions, increases the 
antioxidant capacity of tumors, thereby countering the 
oxidative stress caused by irradiation. 
Interestingly, analysis of glucose transporter (GLUT1) and 
monocarboxylate transporter (MCT4) expression on the 
histological level suggested a different metabolism for 
adenocarcinomas and squamous cell carcinomas of the lung. 
Results showed that adenocarcinomas rely mainly on aerobic 
glycolysis, whereas the energy metabolism of squamous cell 
carcinomas is more physiologically, i.e. mitochondrial 
